Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, dose-escalating, 48-week study assessing the safety,
tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1
mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with
Diabetic Macular Edema (DME).